We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

MtQ5.0

MitoQ Research

Mostly mechanism / observationalHigh safety

7 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most MitoQ studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from medium-quality randomised trials published 2010–2023 with a typical study size of 23 participants.

Based on 7 studies · 6 RCTs · 230 total participants

Confidence

Moderate

By outcome

Vascular & endothelial functionImproved endothelial (flow-mediated dilation) function; small short-term vascular RCTs · 6 weeks
Mostly mechanism / observational3 studies
Aging & healthspan (emerging)Mitochondrial-ROS rationale for vascular aging; human data are surrogate markers, not lifespan · Long-term
Too few graded studies1 study
Neuroprotection & brain agingMechanistic appeal, but the largest Parkinson's RCT found no disease-modifying effect · Unproven
Too few graded studies1 study
Liver health
Too few graded studies1 study
Endurance & exercise performanceAcute vascular/exercise-tolerance gains in PAD, but null effect on endurance-training adaptation in healthy adults · Mixed
Too few graded studies1 study
Safety profile
Too few graded studies1 study

By the numbers

Pulled from 7 studies with measurable effects

People studied

230

typical study: 23 people

Strongest designs

0 pooled, 6 randomised

How long studies ran

1–4 weeks

1–3 months

3+ months

Populations Studied

Newly diagnosed untreated Parkinson's disease1

Healthy older adults with impaired endothelial function1

Young healthy men1

Chronic hepatitis-C patients1

Steady research

1 study in the last 5 years

201020162023

1Parkinson's disease progression (UPDRS)RCTn=128 · medium study2010

We showed no difference between MitoQ and placebo on any measure of PD progression. MitoQ does not slow the progression of PD.

Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O'Sullivan JD, Fung V, Smith RA, Murphy MP, Taylor KM; Protect Study Group · Movement disorders : official journal of the Movement Disorder Society (2010)

PROTECT: multicenter double-blind RCT of 128 newly diagnosed, untreated Parkinson's patients over 12 months
Two MitoQ doses compared with placebo against the Unified Parkinson Disease Rating Scale and other progression measures
No difference between MitoQ and placebo on ANY measure of disease progression

View source

2Brachial-artery flow-mediated dilationRCTn=20 · very small study2018

Brachial artery flow-mediated dilation was 42% higher after MitoQ versus placebo (P<0.05).

Rossman MJ, Santos-Parker JR, Steward CAC, Bispham NZ, Cuevas LM, Gioscia-Ryan RA, Murphy MP, Seals DR · Hypertension (Dallas, Tex. : 1979) (2018)

Randomized, placebo-controlled, double-blind crossover trial in 20 healthy older adults (60-79 yr) with impaired endothelial function
6 weeks of 20 mg/day MitoQ raised brachial-artery flow-mediated dilation by 42% versus placebo
Improvement was linked to reduced mitochondrial-ROS suppression of endothelial function; MitoQ was well tolerated

View source

3VO2max, muscle mitochondrial capacity, circulating angiogenic cellsRCTn=23 · very small study2016

MitoQ supplementation neither enhances nor attenuates endurance training adaptations in young healthy men.

Shill DD, Southern WM, Willingham TB, Lansford KA, McCully KK, Jenkins NT · The Journal of physiology (2016)

Randomized trial of MitoQ vs placebo across 3 weeks of endurance exercise training in young healthy men
Training increased circulating angiogenic cells, muscle mitochondrial capacity (+24%), and VO2max (~7%)
MitoQ had no effect on any of these adaptations — neither enhancing nor blunting them

View source

4Serum aminotransferases (ALT/AST) and HCV RNARCTn=30 · small study2010

Administration of the mitochondria-targeted anti-oxidant mitoquinone significantly decreased plasma ALT and aspartate aminotransferase in patients with chronic HCV infection.

Gane EJ, Weilert F, Orr DW, Keogh GF, Gibson M, Lockhart MM, Frampton CM, Taylor KM, Smith RA, Murphy MP · Liver international : official journal of the International Association for the Study of the Liver (2010)

Phase-II RCT: 30 chronic hepatitis-C patients randomized to mitoquinone (40 or 80 mg) or placebo once daily for 28 days
Significant decreases in serum ALT from baseline to day 28 in the treatment groups
No change in HCV viral load — the effect was on hepatic necroinflammation, not the virus

View source

5Flow-mediated dilation and exercise toleranceRCTn=11 · very small study2020

There were significant group by time interactions for brachial and popliteal FMD that both increased... maximal walking time and distance increased.

Park SY, Pekas EJ, Headid RJ 3rd, Son WM, Wooden TK, Song J, Layec G, Pipinos II · American journal of physiology. Heart and circulatory physiology (2020)

Randomized crossover trial in 11 patients with peripheral artery disease; acute MitoQ vs placebo
Brachial and popliteal flow-mediated dilation increased (Δ2.6% and Δ3.3%) with MitoQ
Maximal walking time (+~74 s), walking distance (+~49 m), and superoxide dismutase activity improved

View source

6Vascular function (FMD) and exercise capacityRCTn=18 · very small study2023

Compared with placebo, MitoQ improved flow-mediated dilation... MitoQ did not affect exercise capacity.

Kirkman DL, Stock JM, Shenouda N, Bohmke NJ, Kim Y, Kidd J, Townsend RR, Edwards DG · American journal of physiology. Renal physiology (2023)

Randomized controlled pilot in 18 stage 3-4 chronic-kidney-disease patients; 4 weeks of 20 mg/day MitoQ vs placebo
MitoQ improved macrovascular (flow-mediated dilation) and microvascular function and blunted arterial-pressure augmentation
MitoQ did NOT improve exercise capacity (cardiopulmonary exercise testing)

View source

7Mechanism of mitochondria-targeted antioxidantsReview2015

Mitochondria-targeted antioxidants, such as MitoQ (composed by the lipophilic triphenylphosphonium cation conjugated to the endogenous antioxidant coenzyme Q10)... accumulate in several hundred-fold greater concentrations within mitochondria.

Ramis MR, Esteban S, Miralles A, Tan DX, Reiter RJ · Current medicinal chemistry (2015)

Review of mitochondria-targeted antioxidants and the rationale that untargeted antioxidants reach mitochondria poorly
Describes MitoQ as CoQ10 conjugated to a triphenylphosphonium (TPP+) cation, accumulating several-hundred-fold within mitochondria
Frames the mechanism by which MitoQ protects the electron transport chain and mitochondrial DNA from oxidative damage

View source

View in Research Library

MitoQ Research

Mostly mechanism / observational

By the numbers

A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease.

Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults.

Mitochondria-specific antioxidant supplementation does not influence endurance exercise training-induced adaptations in circulating angiogenic cells, skeletal muscle oxidative capacity or maximal oxygen uptake.

The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients.

Acute mitochondrial antioxidant intake improves endothelial function, antioxidant enzyme activity, and exercise tolerance in patients with peripheral artery disease.

Effects of a mitochondrial-targeted ubiquinol on vascular function and exercise capacity in chronic kidney disease: a randomized controlled pilot study.

Protective Effects of Melatonin and Mitochondria-targeted Antioxidants Against Oxidative Stress: A Review.